BioNTech SE BNTX
87.65 USD +0.44 (+0.50%)
At closeNov 11, 2026, 4:00 PM EST
87.20 -0.45 -0.51%
After hours · Nov 11, 4:00 PM ET
86.30 Day range 87.73
79.52 52-week range 124.00
- YTD
- -7.93%
- 1 year
- -19.33%
News
fool.com BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis…
benzinga.com BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future…
benzinga.com HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110 HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $110.
fool.com BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed…
247wallst.com Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
fool.com Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027? Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while…
benzinga.com Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106 Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $114 to $106.
benzinga.com Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125 Wells Fargo analyst Mohit Bansal maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $140 to $125.
seekingalpha.com BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade) BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported…
benzinga.com Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110 Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $120 to $110.
seekingalpha.com BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript BioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of…
marketbeat.com BioNTech Q3 Earnings Call Highlights BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the…
benzinga.com BioNTech Q3 2026 Earnings Call Transcript BioNTech (NASDAQ:BNTX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com BioNTech Q3 Adj. EPS $2.03 Beats $0.97 Estimate, Sales $1.484B Beat $1.170B Estimate BioNTech (NASDAQ:BNTX) reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $0.97 by 109.28 percent. This is a 43.3 percent decrease over earnings of $3.58 per…
- benzinga.com BioNTech Narrows FY2026 Sales Guidance from $1.860B-$2.209B to $1.957B-$2.187B vs $2.020B Est BioNTech (NASDAQ:BNTX) narrows FY2026 sales outlook from $1.860 billion-$2.209 billion to $1.957 billion-$2.187 billion vs $2.020 billion estimate.
globenewswire.com BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart…
247wallst.com Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big…
investopedia.com Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
benzinga.com BioNTech Evaluates Next Steps as Breast Cancer Drug Shows Limited Patient Benefit BioNTech and DualityBio report modest Phase 3 breast cancer survival gains alongside higher lung toxicity, limiting overall patient benefit.
247wallst.com Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
globenewswire.com BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the…
globenewswire.com BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2…
247wallst.com Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked…
reuters.com BioNTech, Gilead to test drug combination in advanced breast cancer trial BioNTech, Gilead to test drug combination in advanced breast cancer trial
benzinga.com BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA…
globenewswire.com BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate…
globenewswire.com BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3,…- benzinga.com BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in…
globenewswire.com BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the…
fool.com Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? BioNTech needs new products to kickstart sales and earnings growth. But two of the company's candidates have experienced setbacks recently.
fool.com Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline A 16.6 billion euro cash balance gives BioNTech room to fund trials, partnerships, and a $1 billion share repurchase program. With 14 pivotal trials underway, including seven for pumitamig,…- benzinga.com Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132 Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.
benzinga.com Why Is BioNTech Stock Falling Tuesday? BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
benzinga.com Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.- benzinga.com BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with…
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
benzinga.com Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114 Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.
benzinga.com Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
benzinga.com Why Is BioNTech Stock Gaining Monday? BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.- benzinga.com BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105 BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.
- benzinga.com Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136 Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.
benzinga.com Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’ Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.
benzinga.com BioNTech Stock Dips After BNT122-01 Trial Termination BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
benzinga.com QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.- benzinga.com FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula 2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to…
benzinga.com Why Is Arbutus Biopharma Stock Gaining Friday? Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
benzinga.com Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED) Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.